New Delhi, 10 July 2018: Delhi Network of Positive People (DNP+) has filed today two patent oppositions before the Indian patent office, challenging additional patent claims by US pharmaceutical corporation-Gilead Sciences for the hepatitis C medicines sofosbuvir and velpatasvir. These oppositions challenge Gilead’s patent applications for the tablet formulation of the fixed-dose combination of sofosbuvir/velpatasvir and the polymorph form of velpatasvir.
Source: MSF | July 09, 2018
Gilead Sciences has applied for multiple patents on oral hepatitis C medicines – sofosbuvir and velpatasvir in India: not only limiting itself to basic patents but also staking claims on a number of additional patents for routine improvements and derivatives. This brief provides technical information based Continue reading
Source: The Hindu | July 02, 2018
Some powers with Customs revoked
The Union Ministry of Finance has amended Intellectual Property rules to revoke the power vested with Customs authorities to seize imported products based on complaints of patent infringement.
On June 22, the Ministry made two amendments to the Intellectual Property Rights (Imported Goods) Enforcement Rules, 2007. Firstly, the Intellectual Property Rights (Imported Goods) Enforcement Amendment Rules, 2018, omits all reference to the Patents Act, 1970. Continue reading
by Tahir Amin, CNBC | June 27, 2018
- One in four Americans are unable to fill prescriptions due to high prices.
- Today’s drug patent monopolies are stronger than at any point in the last century, raising prescription prices.
- Until the U.S. patent system is reformed, the pharmaceutical industry will continue to deny competition, block incentives discoveries and promote ineffective drugs.
by Fran Quigley, Health & Human Rights Journal | June 26, 2018
Access to essential medicines is a well-established component of the human right to health, but it is a right that remains elusive for millions of people across the globe. The United Nations estimates that 10 million people each year die because they cannot afford medicines. Even in the United States one out of every five Americans does not fill a prescription each year because they cannot afford it. Protected by monopoly patents, medicines are routinely priced at levels hundreds of times their manufacturing costs, and far exceeding research investments. The corporations that sell the medicines enjoy record-breaking profits yet still routinely raise prices by double-digit margins each year. Continue reading
By Rema Nagarajan, The Times of India | June 21, 2018
Netherlands health minister Bruno Bruins was in India recently to promote investments in life sciences and health with affordable healthcare being a key concern for both countries. Bruins spoke to the Times of India on the challenges of containing healthcare costs and how the Netherlands could contribute to achieving this.
Will the Netherlands support efforts to make pharma companies reveal how they calculate R&D costs on the basis of which they demand high prices?
Yes, we believe we should put pressure on companies to make their R&D costs transparent. This will allow us to have an informed debate on fair pricing and incentives for innovation. But we need to balance it with the fact that there could be new drugs for diseases and we might not get any new drugs if we push the companies too much. Continue reading